An ergoline is a chemical compound built on a rigid tetracyclic indole-derived scaffold that, across its serotonergically active members, produces psychedelic-class effects ranging from subtle perceptual shifts to full-spectrum alteration of perception, cognition, and the sense of self.[1] Membership is defined by the scaffold itself — four fused rings (A–D), incorporating an indole moiety extended into a partly saturated tetracycle — and not by any single receptor profile or potency range.[2]
The class spans natural and synthetic compounds that share this ring system. Natural members include LSA (d-lysergic acid amide) and the ergoline alkaloids of Morning glory seeds; the synthetic members include LSD and a wider series of lysergamide analogues — among them 1P-LSD, 1cP-LSD, 1V-LSD, ALD-52, AL-LAD, ETH-LAD, LSZ, and MiPLA. Despite wide variation in substitution and potency, all converge on serotonergic activity, above all partial agonism at the 5-HT2A receptor.
Ergolines are encountered in research contexts, in traditional practices associated with the seeds of certain Convolvulaceae plants, and recreationally — most prominently as LSD. Their effects scale with exposure: at low intensity, mild perceptual and emotional sensitivity; at moderate intensity, structured visual phenomena and non-linear cognition; at higher intensity, immersive perceptual change and dissolution of the ordinary sense of self.[1] Active durations are characteristically long compared with most other serotonergic psychedelics.
Pharmacology
The convergent endpoint for psychedelic activity across the class is partial agonism at the serotonin 5-HT2A receptor, expressed at high density on cortical pyramidal neurons.[1] Members differ in affinity, intrinsic efficacy, and pharmacokinetics, but they reach this same target — the variation sits on the peripheral scaffold, not on the underlying mechanism.
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Direct 5-HT2A partial agonism | LSD, ETH-LAD, AL-LAD, LSZ, MiPLA | Binds 5-HT2A directly; activation of cortical 5-HT2A receptors drives the psychedelic effect[1] |
| N1-acyl prodrugs hydrolysed to an active lysergamide | 1P-LSD, 1cP-LSD, 1B-LSD, 1V-LSD, ALD-52 | Hydrolysis of the N1-acyl group in serum yields LSD (or, for the AL-LAD- and MiPLA-derived acyl variants, the corresponding parent lysergamide), which then acts at 5-HT2A[3] |
| Lower-affinity natural ergolines | LSA, Morning glory seed alkaloids | Same scaffold and same 5-HT2A mechanism, but at reduced affinity and with a qualitatively more sedating profile[4] |
The rigid ergoline scaffold overlaps sterically with both the tryptamine and the phenylethylamine pharmacophores, which is why class members bind broadly across the serotonin receptor family — including 5-HT1A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7 — as well as dopamine D2 and adrenergic receptors.[5]
This polypharmacology distinguishes ergolines from the structurally simpler tryptamine and phenethylamine psychedelics. Among the secondary targets, 5-HT2B agonism is pharmacologically notable because sustained 5-HT2B stimulation has been linked to cardiac valvulopathy in non-psychedelic contexts; no verified cases of ergoline-associated valve disease have been reported in the clinical literature.[6]
Substances
The class includes natural alkaloids, the prototypical synthetic lysergamide LSD, and a wider research-chemical series of N1-acyl and amide-substituted analogues.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| LSD | Lysergamide | The prototypical and most extensively studied ergoline; diethylamide at C-8 |
| 1P-LSD | N1-acyl lysergamide | Propionyl group at N1; widely characterised as a prodrug for LSD |
| 1cP-LSD | N1-acyl lysergamide | Cyclopropanoyl group at N1; hydrolyses to LSD in human serum[3] |
| ALD-52 | N1-acyl lysergamide | Acetyl group at N1; an early-reported N1-acyl LSD analogue |
| AL-LAD | Amide variant | Allyl substitution at the C-8 amide; broadly LSD-like in character with a shorter active window |
| ETH-LAD | Amide variant | Ethyl/propyl amide substitution at C-8; altered potency and qualitative texture relative to LSD |
| LSZ | Amide variant | Azetidide ring in place of the diethylamide; rigid amide constrains conformation |
| LSA | Natural ergoline | d-lysergic acid amide; the principal psychoactive alkaloid of ergot and certain seeds, with markedly lower 5-HT2A potency than LSD |
| Morning glory | Natural plant source | Seeds of certain Ipomoea and Turbina species; LSA and related ergolines are their principal psychoactive constituents |
These members differ widely in potency, duration, and qualitative character, but they share the tetracyclic scaffold and converge on the same primary serotonergic mechanism. The N1-acyl analogues in particular have very limited human pharmacological literature; their characterisation rests on in-vitro serum metabolism studies and rodent behavioural data.[3]
Subjective Effects
Across the class the subjective trajectory follows the degree of 5-HT2A engagement, from subtle perceptual sensitivity to full-spectrum alteration of perception and self.[1]
| Exposure | Characteristic effects |
|---|---|
| Low | Subtle changes in colour and edge perception, mild emotional sensitivity, slight stimulation, and modest alterations in associative thinking |
| Moderate–high | Complex and structured visual phenomena, non-linear cognitive associations, time distortion, fluid boundaries between self and environment, and pronounced emotional amplification |
| High | Immersive perceptual alteration, dissolution of the ordinary sense of self ("ego dissolution"), full-field visual reorganisation, and prolonged subjective time |
The same 5-HT2A-mediated axis drives both the sought perceptual and emotional shifts and the more challenging states that can accompany them, so the margin between absorbing and overwhelming experience narrows as exposure rises.
Autonomic effects — heart rate elevation, pupil dilation, mild blood pressure increase — are characteristic of the class and consistent with its sympathomimetic component; they are generally mild at common exposure levels.[5]
Active durations are characteristically long relative to other serotonergic psychedelic classes. LSA and Morning glory seeds occupy the lower end of the trajectory — their experience is described in the literature as more sedating and dreamy, with less visual complexity and more pronounced nausea, than the potent synthetic lysergamide members.[4]
Safety
Risk profile
The defining acute risks of the ergoline class are psychological. Severe anxiety, panic, paranoia, and dysphoric states are dose-dependent and more likely under adverse set-and-setting conditions.[6] In individuals with a personal or family history of schizophrenia or other psychotic disorders, ergolines can precipitate psychotic decompensation — this is the most clearly established contraindication for the class and for serotonergic psychedelics more broadly.
A small subset of users develops hallucinogen persisting perception disorder (HPPD), a rare condition characterised by persistent visual disturbances after use has ceased. HPPD is documented across the classic psychedelic classes and is most frequently associated with LSD, though its pathophysiology remains incompletely understood.[6]
Acute sympathomimetic effects — transient rises in heart rate and blood pressure — are characteristic of the class. At single exposures these are generally clinically insignificant in healthy individuals, but pre-existing cardiovascular conditions add risk.
Long-term repeated exposure raises a theoretical concern about cardiac valvulopathy through chronic 5-HT2B agonism, the mechanism established for non-psychedelic serotonergic drugs; no verified cases of ergoline-associated valve disease have been reported in the clinical literature, but long-term repeated-use data do not exist at scale.[6]
Because ergolines act as serotonin receptor agonists, co-administration with other serotonergic agents — SSRIs, MAOIs, SNRIs, lithium, and other serotonergic substances — carries a theoretical risk of serotonin syndrome. The class-wide principle applies even where clinical documentation is thin: combining ergolines with serotonergic medications is a recognised risk pattern.
Beyond pharmacological interactions, the profound and long-lasting alteration of perception and cognition substantially impairs the capacity to operate vehicles or machinery and to manage time-sensitive situations during the active window.
Tolerance & dependence
Tolerance to ergoline-class compounds develops extremely rapidly — more so than for most other psychoactive classes. Daily administration of LSD produces near-complete loss of perceptual effect within roughly four days, an effect attributed to downregulation and desensitisation of cortical 5-HT2A receptors with β-arrestin2 involvement.[4][7] Tolerance cannot be practically overcome by dose escalation and reverses spontaneously after a period of abstinence. Cross-tolerance is robust within the class and extends to other 5-HT2A psychedelics, including psilocybin-bearing tryptamines and the phenethylamine psychedelics.[7]
Ergolines do not produce physical dependence. No withdrawal syndrome has been described for LSD or any related ergoline; animals do not self-administer LSD under the standard preclinical paradigm, and the human clinical literature finds no craving phenomenology characteristic of dependence.[8][1] The rapid tolerance mechanism is itself a strong pharmacological brake against compulsive daily use — effects do not recur at the same intensity if exposure is frequent.
Recovery
Because ergolines do not produce physical dependence, problematic patterns of use are addressed as behavioural and psychological concerns rather than as a physiological withdrawal — there is no medical taper to manage. Difficult acute experiences typically resolve as the substance clears; prolonged or distressing after-effects, including anxiety, intrusive imagery, or HPPD-related disturbances, are addressable through psychological support and integration work. A clinician, therapist, or psychedelic-integration service can help with persistent sequelae or with patterns of use a person wishes to change.Recovery resources, crisis lines, and support pathways → View all
Sub-classes
Members
references
- [1]
- [2]^Tuck, J.R. and Dunlap, L.E. and Olson, D.E. (2023) Synthetic Strategies toward Lysergic Acid Diethylamide: Ergoline Synthesis via α-Arylation, Borrowing Hydrogen Alkylation, and C–H Insertion — Journal of Organic Chemistry doi:10.1021/acs.joc.3c01363
- [3]^abcBrandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU et al. (2020) Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD) — Drug Testing and Analysis doi:10.1002/dta.2789
- [4]^abcHalberstadt AL (2015) Recent advances in the neuropsychopharmacology of serotonergic hallucinogens — Behavioural Brain Research doi:10.1016/j.bbr.2014.07.016
- [5]^abPassie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review — CNS Neuroscience and Therapeutics doi:10.1111/j.1755-5949.2008.00059.x
- [6]^abcdSchlag AK, Aday J, Salam I, Neill JC, Nutt DJ (2022) Adverse effects of psychedelics: From anecdotes and misinformation to systematic science — Journal of Psychopharmacology doi:10.1177/02698811211069100